Physician

Andres Felipe Gutierrez Ordonez, M.D.

According to 2025 Medicare claims, Andres Ordonez, M.D. (NPI: 1134452279) practices infectious disease in the Huntsville, AL market, with the plurality of this provider's patient population coming from Madison, AL. This provider's primary affiliated billing organization is METRO INFECTIOUS DISEASE CONSULTANTS, LLC (NPI: 1235125717; TIN: 363966745) and primary practice location at 35801-5029. Ordonez is affiliated with the American Choice Healthcare, LLC (ACO ID: D0086), participating under the REACH model.

Ordonez's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 553 traditional Medicare patients, billed 44,868 HCPCS/CPT codes, and received $903,912 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 606 prescription claims across 121 beneficiaries totaling $341,537 in drug costs, led by Symtuza (Darunavir/Cob/Emtri/Tenof Alaf). 2021 DME data shows 13 claims. Open Payments data shows 7 records totaling $567. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $79,907 to $903,912. Similarly, Part D prescription costs have risen steadily, from $76,060 to $341,537. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	236	1,618	$79,907
2016	639	14,099	$221,241
2017	600	42,238	$335,949
2018	528	38,052	$697,906
2019	478	34,539	$1,360,682
2020	526	33,382	$1,476,999
2021	536	55,633	$748,130
2022	579	74,740	$807,131
2023	593	60,749	$637,584
2024	553	44,868	$903,912

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	20	146	$76,060
2016	70	424	$252,461
2017	77	404	$214,845
2018	113	464	$310,677
2019	88	458	$333,926
2020	117	504	$258,686
2021	86	465	$242,475
2022	107	569	$310,416
2023	120	616	$330,279
2024	121	606	$341,537

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	13	$21,862
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	188	197	$125
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	68	113	$90
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	310	1,125	$86
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	89	213	$43
36415	Insertion of needle into vein for collection of blood sample	39	54	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Symtuza	Darunavir/Cob/Emtri/Tenof Alaf	12	360	$64,551
Daptomycin	Daptomycin	100	685	$58,095
Cefepime Hcl	Cefepime Hcl	52	342	$11,354
Vancomycin Hcl	Vancomycin Hcl	30	227	$4,403
Ceftriaxone	Ceftriaxone Sodium	29	200	$3,659

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$567	La Jolla Pharmaceutical Company
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andres Felipe Gutierrez Ordonez, M.D.?

Tedicare shows public-source Medicare data for Andres Felipe Gutierrez Ordonez, M.D. (NPI 1134452279), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andres Felipe Gutierrez Ordonez, M.D. have ACO affiliation data?

Andres Felipe Gutierrez Ordonez, M.D. is shown with ACO affiliation data for American Choice Healthcare, LLC (REACH, ACO ID D0086).

What billing organization is linked to Andres Felipe Gutierrez Ordonez, M.D.?

Andres Felipe Gutierrez Ordonez, M.D. is linked to METRO INFECTIOUS DISEASE CONSULTANTS, LLC (billing NPI 1235125717) in the available physician profile data.

Does Andres Felipe Gutierrez Ordonez, M.D. have Open Payments data?

Andres Felipe Gutierrez Ordonez, M.D. has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.